Press Releases

April 23, 2025
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology LOUISVILLE, Colo. and HERCULES, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc (Nasdaq: BDSX), a leading
March 3, 2025
Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023 ; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., March 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc.
February 26, 2025

BOULDER, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at TD